Immunotherapy clinical trial assesses opportunity to prevent lung...
An immunotherapy used against advanced non-small cell lung cancer is being tested at MD Anderson for a different job: preventing the...
Metastatic cells, mechanisms of drug resistance identified...
Researchers at The University of Texas MD Anderson Cancer Center have discovered important mechanisms of drug resistance and...
Combination therapy key in two studies of blood cancers...
Results from two MD Anderson studies demonstrated the significance of combination therapy in follicular lymphoma and chronic...
Immunotherapy innovation: Moon Shots effort aims natural killer...
MD Anderson’s adoptive cell therapy (ACT) platform is advancing the next generation of cell-based immune therapies to bring innovative...
Moon Shot deploys policy help, education and clinical trial...
November is Lung Cancer Awareness Month, and the third Thursday of each November is designated by the American Cancer Society as the...
Moon Shot promotes efforts to prevent, quickly detect...
Each year in the U.S., more than 50,000 people will be diagnosed with pancreatic cancer, which ranks around the 10th most common...
Mutations in tumor-adjacent tissues could reveal earliest...
MD Anderson researchers have identified early genomic events that may lead to malignant transformation. They’ve found that tissue...
Immunotherapy combination is greater than the sum of its...
Combining two types of immune checkpoint inhibitor fires up responses in T cells that are separate from those initiated by the two...
E-cigarettes: Unstandardized, under-regulated,...
The recent outbreak of lung injury and death associated with e-cigarettes and vaping has led to a renewed scrutiny of electronic...
TRACTION accelerates translation of discoveries into new...
Despite major recent advances in oncology drug discovery, including the development of innovative targeted, immune and cell-based...
Computer-assisted design technology complements navigation...
Combining a 3D virtual cutting guide with a surgical navigation tool allowed MD Anderson surgeons to perform a complicated pelvic...
APOLLO’s high-quality longitudinal samples empower cancer...
Cancer’s ability to evolve in response to treatment and develop resistance to available therapies is one of the most significant...
Multiple studies show major lack of public knowledge about...
Despite the fact that the human papillomavirus (HPV) vaccine has been available in the U.S. for over 10 years and remains the only...
Moon Shot rises to challenge of glioblastoma
Glioblastoma (GBM) is not among the most commonly diagnosed cancers in the U.S., but it can certainly be among the most devastating....
Lung cancer targeted therapy hits common HER2 variants...
Building upon the foundational discovery that the targeted therapy poziotinib is a potent and selective inhibitor of specific EGFR and...
Breast, ovarian cancer trials find targeted therapies...
Results from two The University of Texas MD Anderson Cancer Center-led clinical trials indicate that targeted therapies led to...
Studies show early success for pre-surgical immunotherapy...
Early results from two MD Anderson studies show promising responses to neoadjuvant (pre-surgical) checkpoint inhibitors in patients...
Study identifies novel therapeutic approach for head and...
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer globally. Even with multimodality treatment, including...
AML drug may be good for KRAS-driven pancreatic cancer,...
Repurposing FDA-approved therapies is a cost-effective way to bring new treatments to patients in need, but identifying those drugs...
Predicting head and neck cancer treatment toxicities with...
MD Anderson researchers have developed the first machine learning algorithm to predict acute toxicities in patients receiving...
Moon Shot concentrates on treating, preventing high-risk...
Multiple myeloma is the second most common hematological malignancy in the United States, and it’s increasing in incidence. An...
Research finds evidence HPV vaccine is improving herd...
A study from researchers at The University of Texas MD Anderson Cancer Center found that the prevalence of the types of oral human...
Vaguely seen on images, lung nodules’ genomics outline...
Small precancerous growths in the lungs are capable of progressing to invasive lung cancer, but so little has been known about them...
Study finds women disproportionally absent from clinical...
Even as women have gained ground in oncology, they remain under-represented as leaders of phase III clinical trials, MD Anderson...
Triple combination therapy with nivolumab is feasible for...
The addition of nivolumab to induction chemotherapy with idarubicin and cytarabine is feasible in patients with newly diagnosed acute...
Moon Shot confronts challenges of multiple cancers driven...
According to the Centers for Disease Control and Prevention, the human papillomavirus is responsible for roughly 33,700 new cancer...
Study defines genetic pathway for hard-to-treat form of...
A study at The University of Texas MD Anderson Cancer Center has shed information on a novel oncogenic pathway and points to the use...
Moon Shot helps corner aggressive-variant prostate cancer
Prostate cancer is the most common cancer diagnosed in American men, and the second leading cause of cancer death in men. While...
Blocking protein reduces fibrosis, thwarts ovarian and...
Using an antibody to plug a protein secreted by fibrous tissues in tumors stifles ovarian and pancreatic cancer in mouse models by...
New approach enhances PD-L1 detection to aid in...
Just as a driver’s night vision improves by simply cleaning the headlights, scientists at The University of Texas MD Anderson Cancer...
International consortium publishes recommendations for...
An international consortium, led in part by clinicians and researchers from The University of Texas MD Anderson Cancer Center, has...
Long non-coding RNA implicated in triple negative breast...
A slice of RNA that doesn’t code for a protein manages to stifle tumor-suppressing genes and wreck the cellular mechanism that flags...
MD Anderson advances novel therapeutic antibody into AML...
Leukemia researchers at The University of Texas MD Anderson Cancer Center, working collaboratively with the Therapeutics Discovery...
Triple combination shows promise against advanced melanoma
Combining two types of drugs that, separately, have extended the lives of people with metastatic melanoma has yielded higher response...
V. Craig Jordan honored by Queen Elizabeth II for impact on...
V. Craig Jordan, Ph.D., professor of Breast Medical Oncology, has been recognized for his “services to women’s health” with his...
Hortobagyi honored by ASCO for his work against breast...
Improvements in breast cancer treatment over the past five decades have reduced the mortality rate of women with the disease by 40...
Innovative combination clinical trial results revealed at...
MD Anderson researchers will present clinical trial results of promising combination therapies for a variety of cancers at the 2019...
Evolutionary selection of pancreatic cancer cells leads to...
Researchers at The University of Texas MD Anderson Cancer Center have shown how pretreatment clonal complexity in pancreatic tumor...
Novel oncogene hnRNPK identified for B-cell lymphomas
Researchers at MD Anderson Cancer Center have defined a new oncogene for B-cell lymphomas. The cancer-causing gene, known as...
Inducible immune resistance to protect lungs earns...
Immunology research to investigate the mechanisms of a new aerosol treatment, which induces an innate immune response to protect...
Anti-CTLA-4 immunotherapy creates new T cells while freeing...
Nobel Laureate Jim Allison, Ph.D., invented immune checkpoint blockade immunotherapy by blocking the CTLA-4 protein on T cells,...
Amplifying genetic testing to better prevent hereditary...
Testing for BRCA1 and BRCA2 seeks to identify mutations associated with increased risk of developing certain cancers over a person’s...
Combination chemotherapy before blood stem cell transplant...
A randomized Phase III clinical trial combining two common chemotherapy agents as a pre-stem cell transplant treatment at The...
Shielding healthy organs from radiotherapy for pancreatic...
Unresectable pancreatic cancer is usually fatal because other treatments, such as radiation therapy, cannot be used. Radiation therapy...
Study shows early-onset colorectal cancers have distinct...
Through in-depth retrospective analysis of data from more than 36,000 patients, a new study led by researchers at The University of...
Funding that makes a difference for cancer patients
Whether it is new clinical trials for pediatric cancers or programs designed to increase access to smoking cessation programs for...
Pancreatic Cancer Moon Shot sharpens pre-surgical treatment
Neoadjuvant therapy is treatment, such as chemotherapy or radiation, given before a patient has surgery. This approach is used in many...
The search for valuable cancer-related proteins
MD Anderson’s proteomics platform provides a valuable institutional resource, complete with state-of-the-art instruments and...
Treatment advances for CLL, the most common leukemia
Chronic lymphocytic leukemia (CLL), which originates in white blood cells known as lymphocytes, is the most common form of leukemia in...
Immunotherapy before surgery for glioblastoma shows promise
Glioblastoma is the most common, aggressive and deadly form of brain cancer. Median overall survival for primary glioblastoma is 14.6...
Immunotherapy advances in targeting pancreatic, prostate...
This is the second part of Cancer Frontline’s interview with Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical...
Immunotherapy leader details ongoing expansion of cancer...
In October 2018, the Nobel Prize in Physiology or Medicine was awarded to Jim Allison, Ph.D., chair of Immunology, for his discoveries...
$5.1 million grant to expand cervical cancer diagnosis and...
MD Anderson Cancer Center researchers, together with collaborators from Mozambique, Brazil and the U.S., have been awarded a $5.1...
Dream Team targets T-cell lymphoma using CAR-modified cells...
A Dream Team assembled by Stand Up To Cancer will receive $8 million in funding to research the use of modified immune cells to...
What’s next for targeting cancer DNA repair with PARP...
DNA damage response (DDR) inhibitors, such as poly (ADP-ribose) polymerase (PARP) inhibitors, are a type of targeted therapy used to...
Expressive writing improves quality of life for breast...
Receiving a cancer diagnosis is a life-changing event, and the path through treatment can be among the hardest things a person goes...
Cutting-edge MRI-guided radiation therapy provides...
An innovative new technology is now providing radiation oncologists at MD Anderson Cancer Center a real-time view of tumors while they...